Venúcia B M Pereira1, Anielle T Melo1, Eudmar M Assis-Júnior1, Deysi V T Wong1, Gerly A C Brito2, Paulo R C Almeida3, Ronaldo A Ribeiro1, Roberto C P Lima-Júnior4. 1. Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Rua Cel Nunes de Melo, 1315, Rodolfo Teófilo, Fortaleza, Ceará, 60430-270, Brazil. 2. Department of Morphology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil. 3. Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil. 4. Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Rua Cel Nunes de Melo, 1315, Rodolfo Teófilo, Fortaleza, Ceará, 60430-270, Brazil. robertocesarpljr@gmail.com.
Abstract
PURPOSE: Intestinal mucositis (IM) is a common side effect of anticancer agents. Despite polychemotherapy use in clinical practice, the pathogenesis of IM has been investigated in single drug injection animal models. However, the progression of IM could vary according to drug regimens. Thus, we aimed to develop a new experimental mucositis model induced by combining irinotecan and 5-fluorouracil (5-FU) treatments. METHODS: IM was induced in male C57BL/6 mice by the intraperitoneal administration of either 0.9 % saline (5 mL/kg), irinotecan (IRI, 30 or 45 mg/kg), 5-FU (25, 37.5, or 50 mg/kg), or the combination of these doses (IRI + 5-FU) for 4 days. Animal survival, body mass variation, and diarrhea scores were evaluated daily. On the 7th day, the mice were euthanized, and intestinal samples were collected for histopathology and morphometric analysis, as well as for the determination of myeloperoxidase activity and cytokine dosage (TNF-α and IL-6). RESULTS: The optimal dose combination that induced IM and presented no substantial mortality on the 7th day was IRI (45 mg/kg) + 5-FU (37.5 mg/kg), which was used for subsequent studies. IRI and 5-FU in combination induced significant diarrhea, body weight loss, intestinal damage, inflammatory cell infiltration, and increased levels of cytokines when compared with other groups (P < 0.05). Neither IRI nor 5-FU alone induced IM. CONCLUSIONS: We developed a new experimental model of IM induced by combining irinotecan and 5-FU treatments, which will allow us to gain a better knowledge concerning the pathogenesis of this disease through the pharmacological modulation of key inflammatory mediators.
PURPOSE:Intestinal mucositis (IM) is a common side effect of anticancer agents. Despite polychemotherapy use in clinical practice, the pathogenesis of IM has been investigated in single drug injection animal models. However, the progression of IM could vary according to drug regimens. Thus, we aimed to develop a new experimental mucositis model induced by combining irinotecan and 5-fluorouracil (5-FU) treatments. METHODS: IM was induced in male C57BL/6 mice by the intraperitoneal administration of either 0.9 % saline (5 mL/kg), irinotecan (IRI, 30 or 45 mg/kg), 5-FU (25, 37.5, or 50 mg/kg), or the combination of these doses (IRI + 5-FU) for 4 days. Animal survival, body mass variation, and diarrhea scores were evaluated daily. On the 7th day, the mice were euthanized, and intestinal samples were collected for histopathology and morphometric analysis, as well as for the determination of myeloperoxidase activity and cytokine dosage (TNF-α and IL-6). RESULTS: The optimal dose combination that induced IM and presented no substantial mortality on the 7th day was IRI (45 mg/kg) + 5-FU (37.5 mg/kg), which was used for subsequent studies. IRI and 5-FU in combination induced significant diarrhea, body weight loss, intestinal damage, inflammatory cell infiltration, and increased levels of cytokines when compared with other groups (P < 0.05). Neither IRI nor 5-FU alone induced IM. CONCLUSIONS: We developed a new experimental model of IM induced by combining irinotecan and 5-FU treatments, which will allow us to gain a better knowledge concerning the pathogenesis of this disease through the pharmacological modulation of key inflammatory mediators.
Authors: Sung Kyun Yim; Kyoung Min Kim; Chang-Hoon Lee; Eun-Kee Song; Seung Ok Lee; Sang Wook Kim; In Hee Kim; Seong-Hun Kim; Seung Young Seo; Soo Teik Lee Journal: In Vivo Date: 2021 May-Jun Impact factor: 2.155
Authors: A T Sougiannis; B N VanderVeen; R T Enos; K T Velazquez; J E Bader; M Carson; I Chatzistamou; M Walla; M M Pena; J L Kubinak; M Nagarkatti; J A Carson; E A Murphy Journal: Brain Behav Immun Date: 2019-02-23 Impact factor: 19.227
Authors: Ludmila T Nogueira; Deiziane V S Costa; Antoniella S Gomes; Conceição S Martins; Angeline M H P Silva; Juliana M Coelho-Aguiar; Patrícia Castelucci; Roberto C P Lima-Júnior; Renata F C Leitão; Vivaldo Moura-Neto; Gerly A C Brito Journal: J Neuroinflammation Date: 2017-04-07 Impact factor: 8.322
Authors: Jake M Bieber; Laura E Sanman; Xiaoxiao Sun; Heinz Hammerlindl; Feng Bao; Maike A Roth; Megan L Koleske; Liusheng Huang; Fran Aweeka; Lani F Wu; Steven J Altschuler Journal: Commun Biol Date: 2022-01-27